armillaridin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

armillaridin: isolated from Armillaria mellea mycelium I; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	51351607
CHEMBL ID	1762764
CHEBI ID	185923
MeSH ID	M0128079

Synonyms (4)

Synonym
armillaridin
[(2r,2as,4as,7as,7br)-3-ormyl-2a-hydroxy-6,6,7b-trimethyl-1,2,4a,5,7,7a-hexahydrocyclobuta[e]inden-2-yl] 3-chloro-6-hydroxy-4-methoxy-2-methylbenzoate
CHEBI:185923
CHEMBL1762764

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

Class	Description
sesquiterpenoid	Any terpenoid derived from a sesquiterpene. The term includes compounds in which the C15 skeleton of the parent sesquiterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
benzoate ester	Esters of benzoic acid or substituted benzoic acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (9)

Assay ID	Title	Year	Journal	Article
AID589479	Cytotoxicity against human Jurkat cells	2011	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7	In vitro cytotoxicity of melleolide antibiotics: structural and mechanistic aspects.
AID589480	Cytotoxicity against human HeLa cells	2011	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7	In vitro cytotoxicity of melleolide antibiotics: structural and mechanistic aspects.
AID1183884	Cytotoxicity against human MONO-MAC-6 cells after 24 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Melleolides induce rapid cell death in human primary monocytes and cancer cells.
AID589481	Cytotoxicity against human K562 cells	2011	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7	In vitro cytotoxicity of melleolide antibiotics: structural and mechanistic aspects.
AID1183883	Cytotoxicity against human THP1 cells after 24 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Melleolides induce rapid cell death in human primary monocytes and cancer cells.
AID1183885	Cytotoxicity against human primary monocytes after 24 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Melleolides induce rapid cell death in human primary monocytes and cancer cells.
AID589478	Cytotoxicity against human MCF7 cells	2011	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7	In vitro cytotoxicity of melleolide antibiotics: structural and mechanistic aspects.
AID1183886	Cytotoxicity against human K562 cells after 24 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Melleolides induce rapid cell death in human primary monocytes and cancer cells.
AID1183887	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Melleolides induce rapid cell death in human primary monocytes and cancer cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (14.29)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	6 (85.71)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	7 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
adenine [no description available]	2.21	1	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
carbonyl cyanide m-chlorophenyl hydrazone Carbonyl Cyanide m-Chlorophenyl Hydrazone: A proton ionophore. It is commonly used as an uncoupling agent and inhibitor of photosynthesis because of its effects on mitochondrial and chloroplast membranes.. CCCP : A member of the class of monochlorobenzenes that is benzene substituted by 2-(1,3-dinitrilopropan-2-ylidene)hydrazinyl and chloro groups at positions 1 and 3, respectively. It is a mitochondrial depolarizing agent that induces reactive oxygen species mediated cell death.	2.1	1	hydrazone; monochlorobenzenes; nitrile	antibacterial agent; geroprotector; ionophore
erythrosine Fluoresceins: A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.	2.11	1
cycloheximide Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.	2.48	2	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor
staurosporine [no description available]	2.1	1	indolocarbazole alkaloid; organic heterooctacyclic compound	apoptosis inducer; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; geroprotector
diacetyldichlorofluorescein diacetyldichlorofluorescein: stable storage form of dichlorofluorescein	2.11	1
dactinomycin Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)	2.48	2	actinomycin	mutagen
sesquiterpenes [no description available]	3.15	5
pretubulysin pretubulysin: from myxobacteria; structure in first source	2.1	1
3-methyladenine N3-methyladenine: structure in first source	2.21	1

Condition	Relationship Strength	Studies
Hepatocellular Carcinoma [description not available]	7.21	1
Cancer of Liver [description not available]	2.21	1
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.21	1
Liver Neoplasms Tumors or cancer of the LIVER.	2.21	1
Granulocytic Leukemia, Chronic [description not available]	2.13	1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.	2.13	1

chemdatabank.com